Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of$ 0.42 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 11.90%. A quarter ago, it was expected that this drug developer would post earnings of$ 0.37 per share when it actually produced earnings of $0.84, delivering a surprise of 127.03%. Over the last four quarters, the compan ...